By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Investment firm William Blair has initiated coverage of Qiagen with a "Market Perform" rating and estimated adjusted earnings per share in 2011 of $.98 and EPS in 2012 of $1.17, after factoring in the acquisition of Cellestis announced earlier this week.

For 2011, analyst Brian Weinstein estimates Qiagen's revenues to be $1.17 billion, while in 2012 he estimates revenues will total $1.27 billion.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: omic analysis of permafrost microbes, hookworm genome, and more.

Biologists turn to environmental DNA sampling to determine whether elusive or invasive species are shedding DNA in a given area.

Rob Knight writes at Scientific American that microbiome studies are about to break out of the laboratory.

Harold Varmus, the director of the National Cancer Institute, has announced that he is stepping down after nearly five years.